Values First Advisors, Inc. Athersys, Inc Transaction History

Values First Advisors, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 20, 2022	BUY	$0.18 - $0.86 $6,287 - $30,038	34,929 Added 10.04%	382,805 $100,000
Q1 2022 May 03, 2022	BUY	$0.6 - $1.06 $50,682 - $89,539	84,471 Added 32.07%	347,876 $211,000
Q4 2021 Mar 10, 2022	BUY	$0.85 - $1.4 $223,894 - $368,767	263,405 New	263,405 $238,000
Q3 2021 Nov 15, 2022	SELL	$1.33 - $1.77 $172,592 - $229,691	-129,769 Reduced 33.9%	253,036 $337,000
Q2 2021 Nov 15, 2022	SELL	$1.41 - $1.94 $6,636 - $9,131	-4,707 Reduced 1.94%	237,620 $342,000
Q1 2021 Nov 15, 2022	SELL	$1.61 - $2.77 $226,169 - $389,124	-140,478 Reduced 36.7%	242,327 $436,000
Q4 2020 Nov 15, 2022	SELL	$1.55 - $2.24 $11,063 - $15,989	-7,138 Reduced 2.94%	235,327 $412,000
Q3 2020 Nov 15, 2022	BUY	$1.91 - $3.08 $46,006 - $74,187	24,087 Added 11.03%	242,465 $473,000
Q2 2020 Nov 15, 2022	BUY	$1.97 - $3.98 $95,675 - $193,292	48,566 Added 28.6%	218,378 $603,000
Q1 2020 Jan 09, 2023	BUY	$1.17 - $3.0 $260,358 - $667,587	222,529 New	222,529 $668 Million
Q4 2019 Nov 15, 2022	SELL	$1.16 - $1.42 $247,071 - $302,450	-212,993 Reduced 55.64%	169,812 $209,000

Ticker ATHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 305,110,016
Market Cap $3.05M
Description
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product i...

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Values First Advisors, Inc. with notifications on news.